Pitavastatin versus Atorvastatin: Potential Differences in their Effects on Serum Lipoprotein Lipase and Cardiovascular Disease.
作者信息
Kobayashi Junji
机构信息
Health Care Center, Inoue Memorial Hospital.
出版信息
J Atheroscler Thromb. 2022 Apr 1;29(4):448-450. doi: 10.5551/jat.ED170. Epub 2021 Apr 1.
Abstract
摘要
相似文献
1
Pitavastatin versus Atorvastatin: Potential Differences in their Effects on Serum Lipoprotein Lipase and Cardiovascular Disease.匹伐他汀与阿托伐他汀：它们对血清脂蛋白脂肪酶和心血管疾病影响的潜在差异
J Atheroscler Thromb. 2022 Apr 1;29(4):448-450. doi: 10.5551/jat.ED170. Epub 2021 Apr 1.
2
Prevention of Cardiovascular Events with Pitavastatin is Associated with Increased Serum Lipoprotein Lipase Mass Level: Subgroup Analysis of the TOHO-LIP.使用匹伐他汀预防心血管事件与血清脂蛋白脂肪酶质量水平升高相关：TOHO-LIP 的亚组分析。
J Atheroscler Thromb. 2022 Apr 1;29(4):451-463. doi: 10.5551/jat.62141. Epub 2021 Feb 27.
3
Atorvastatin and pitavastatin enhance lipoprotein lipase production in L6 skeletal muscle cells through activation of adenosine monophosphate-activated protein kinase.阿托伐他汀和匹伐他汀通过激活腺苷一磷酸激活蛋白激酶增强 L6 骨骼肌细胞中脂蛋白脂肪酶的产生。
Metabolism. 2012 Oct;61(10):1452-60. doi: 10.1016/j.metabol.2012.03.010. Epub 2012 Apr 19.
4
Pitavastatin: the newest HMG-CoA reductase inhibitor.匹伐他汀：最新的 HMG-CoA 还原酶抑制剂。
Rev Cardiovasc Med. 2010 Winter;11(1):26-32. doi: 10.3909/ricm0535.
5
Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study.匹伐他汀与阿托伐他汀对高危患者外周血内皮祖细胞及血管内皮生长因子的影响：一项前瞻性、双盲、随机对照的初步研究
Cardiovasc Diabetol. 2014 Jul 16;13:111. doi: 10.1186/s12933-014-0111-1.
6
CAVI-Lowering Effect of Pitavastatin May Be Involved in the Prevention of Cardiovascular Disease: Subgroup Analysis of the TOHO-LIP.匹伐他汀降低 CAVI 的作用可能与预防心血管疾病有关：TOHO-LIP 的亚组分析。
J Atheroscler Thromb. 2021 Oct 1;28(10):1083-1094. doi: 10.5551/jat.60343. Epub 2020 Dec 18.
7
Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease.匹伐他汀与阿托伐他汀治疗对动脉粥样硬化性心血管疾病高危高胆固醇血症患者的疗效比较
Int J Cardiol. 2020 Apr 15;305:139-146. doi: 10.1016/j.ijcard.2020.01.006. Epub 2020 Jan 20.
8
Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes.匹伐他汀增强了3T3-L1前脂肪细胞中脂蛋白脂肪酶的表达。
J Atheroscler Thromb. 2005;12(3):163-8. doi: 10.5551/jat.12.163.
9
Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling.使用非空腹血样比较阿托伐他汀、匹伐他汀和瑞舒伐他汀对残余心血管风险的影响。
Scand J Clin Lab Invest. 2014 Jun;74(4):285-95. doi: 10.3109/00365513.2014.882015. Epub 2014 Feb 24.
10
Pitavastatin: an overview.匹伐他汀：概述
Atheroscler Suppl. 2011 Nov;12(3):271-6. doi: 10.1016/S1567-5688(11)70886-8.
本文引用的文献
1
Prevention of Cardiovascular Events with Pitavastatin is Associated with Increased Serum Lipoprotein Lipase Mass Level: Subgroup Analysis of the TOHO-LIP.使用匹伐他汀预防心血管事件与血清脂蛋白脂肪酶质量水平升高相关：TOHO-LIP 的亚组分析。
J Atheroscler Thromb. 2022 Apr 1;29(4):451-463. doi: 10.5551/jat.62141. Epub 2021 Feb 27.
2
High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.高剂量与低剂量培伐他汀在日本稳定型冠状动脉疾病患者中的应用（REAL-CAD）：一项随机优势试验。
Circulation. 2018 May 8;137(19):1997-2009. doi: 10.1161/CIRCULATIONAHA.117.032615.
3
Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia.阿托伐他汀和匹伐他汀对血脂异常患者炎症、胰岛素抵抗及颈动脉内膜中层厚度的不同影响。
J Atheroscler Thromb. 2015;22(11):1158-71. doi: 10.5551/jat.29520. Epub 2015 Jun 17.
4
Lipoprotein lipase and atherosclerosis.脂蛋白脂肪酶与动脉粥样硬化
Ann Clin Biochem. 2015 Nov;52(Pt 6):632-7. doi: 10.1177/0004563215590451. Epub 2015 May 20.
5
Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling.使用非空腹血样比较阿托伐他汀、匹伐他汀和瑞舒伐他汀对残余心血管风险的影响。
Scand J Clin Lab Invest. 2014 Jun;74(4):285-95. doi: 10.3109/00365513.2014.882015. Epub 2014 Feb 24.
6
Pitavastatin: clinical effects from the LIVES Study.匹伐他汀：LIVES研究的临床效果
Atheroscler Suppl. 2011 Nov;12(3):285-8. doi: 10.1016/S1567-5688(11)70888-1.
7
Pitavastatin increases ABCA1 expression by dual mechanisms: SREBP2-driven transcriptional activation and PPARα-dependent protein stabilization but without activating LXR in rat hepatoma McARH7777 cells.培伐他汀通过双重机制增加 ABCA1 的表达：SREBP2 驱动的转录激活和 PPARα 依赖性蛋白稳定，但在大鼠肝癌 McARH7777 细胞中不激活 LXR。
J Pharmacol Sci. 2011;116(1):107-15. doi: 10.1254/jphs.10241fp. Epub 2011 Apr 27.
8
Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.匹伐他汀和阿托伐他汀对 2 型糖尿病患者脂蛋白亚类的不同影响。
Diabet Med. 2011 Jul;28(7):856-64. doi: 10.1111/j.1464-5491.2011.03240.x.
9
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.与急性冠脉综合征后的中等强度降脂他汀治疗相比，强化降脂他汀治疗可降低复发性心血管事件：来自 PROVE IT-TIMI 22（普伐他汀或阿托伐他汀评估与感染治疗-心肌梗死 22 试验）的结果。
J Am Coll Cardiol. 2009 Dec 15;54(25):2358-62. doi: 10.1016/j.jacc.2009.10.005.
10
Serum lipoprotein lipase concentration and risk for future coronary artery disease: the EPIC-Norfolk prospective population study.血清脂蛋白脂肪酶浓度与未来冠心病风险：欧洲癌症与营养前瞻性调查诺福克前瞻性人群研究
Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):637-42. doi: 10.1161/01.ATV.0000201038.47949.56. Epub 2005 Dec 22.
Zotero 插件